Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Cited In for PubMed (Select 12374678)

1.

Random periareolar fine-needle aspiration: the new pap smear of the breast?

Lester J, Yee LD.

J Adv Pract Oncol. 2012 Nov;3(6):411-4. Review.

2.

Difluoromethylornithine: the proof is in the polyamines.

Jeter JM, Alberts DS.

Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429.

3.

Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.

Gamble LD, Hogarty MD, Liu X, Ziegler DS, Marshall G, Norris MD, Haber M.

Front Oncol. 2012 Nov 16;2:162. doi: 10.3389/fonc.2012.00162. eCollection 2012.

4.

Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer.

Hoffman A, Pellenberg R, Drendall CI, Seewaldt V.

Curr Breast Cancer Rep. 2012 Sep;4(3):180-187. Epub 2012 Jun 22.

5.

DFMO: targeted risk reduction therapy for colorectal neoplasia.

Laukaitis CM, Gerner EW.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506. doi: 10.1016/j.bpg.2011.09.007. Review.

6.

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfkuhle J, Liotta LA, Lem S, Baker JC Jr, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL.

Breast Cancer Res Treat. 2012 Apr;132(2):487-98. doi: 10.1007/s10549-011-1609-9. Epub 2011 Jun 7. Erratum in: Breast Cancer Res Treat. 2012 Oct;135(3):925.

7.

Phase II cancer prevention clinical trials.

Szabo E.

Semin Oncol. 2010 Aug;37(4):359-66. doi: 10.1053/j.seminoncol.2010.06.015. Review.

8.

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, Havighurst TC, Carbone PP.

Cancer Prev Res (Phila). 2010 Jan;3(1):35-47. doi: 10.1158/1940-6207.CAPR-09-0096.

9.

Structural biology of S-adenosylmethionine decarboxylase.

Bale S, Ealick SE.

Amino Acids. 2010 Feb;38(2):451-60. doi: 10.1007/s00726-009-0404-y. Epub 2009 Dec 8. Review.

10.

Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study.

Ibarra-Drendall C, Wilke LG, Zalles C, Scott V, Archer LE, Lem S, Yee LD, Lester J, Kulkarni S, Murekeyisoni C, Wood M, Wilson K, Garber J, Gentry C, Stouder A, Broadwater G, Baker JC Jr, Vasilatos SN, Owens E, Rabiner S, Barron AC, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1379-85. doi: 10.1158/1055-9965.EPI-08-1210. Epub 2009 Apr 21.

11.

Ductal lavage is an inefficient method of biomarker measurement in high-risk women.

Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, Ivancic D, Nayar R, Masood S, Rademaker A.

Cancer Prev Res (Phila). 2009 Mar;2(3):265-73. doi: 10.1158/1940-6207.CAPR-08-0119. Epub 2009 Feb 17.

12.

New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues of S-adenosylmethionine.

McCloskey DE, Bale S, Secrist JA 3rd, Tiwari A, Moss TH 3rd, Valiyaveettil J, Brooks WH, Guida WC, Pegg AE, Ealick SE.

J Med Chem. 2009 Mar 12;52(5):1388-407. doi: 10.1021/jm801126a.

13.

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.

14.

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.

15.

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.

Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J.

Br J Cancer. 2007 Jan 15;96(1):110-7. Epub 2006 Dec 12.

16.

Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.

Reichardt W, Hu-Lowe D, Torres D, Weissleder R, Bogdanov A Jr.

Neoplasia. 2005 Sep;7(9):847-53.

17.
18.

Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.

Hudson EA, Howells LM, Gallacher-Horley B, Fox LH, Gescher A, Manson MM.

BMC Cancer. 2003 Jan 14;3:2. Epub 2003 Jan 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk